Market Analysis: Global Carcinoid Syndrome Drug Market
Market Definition: Global Carcinoid Syndrome Drug Market
Carcinoid Syndrome is also known as carcinoid cancer or neuroendocrine tumor carcinoid type is ultra-rare endocrinology disorder develops in patients with carcinoid tumors and is characterized by cutaneous flushing, diarrhea and abdominal cramps. The carcinoid syndrome results from the production of vasoactive substances (including serotonin, bradykinin, histamine, prostaglandins, polypeptide hormones) secreted by the neuroendocrine tumorous cells.
Get More Insights About Global Carcinoid Syndrome Drug Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-carcinoid-syndrome-drug-market
According to the statistics published in the National Organization for Rare Disorders, Inc, it was identified up to 27new cases in every one million people diagnosed with carcinoid tumors in the United States. The certain toxin and change in hormonal chemical substances have largely contributed to the rising prevalence of carcinoid syndrome and accelerating demand of novel therapies are the key factors to the market growth.
Rising awareness about treatment and technological advancement is driving the growth of market
Adoption of unhealthy life style, irregular eating habits and lack of physical exercise also drives the market growth
Rapid adoption of newer formulations and novel dosage forms boosts the market growth
The emergence of drugs used in the treatment of risk associated with neuroendocrine tumor can also drive the growth of this market
High cost involved in treatment and diagnosis restricts the market growth
Lack of expertise and inadequate knowledge about carcinoid syndrome in some developing countries also hinders the market growth
Scientific and major technical challenges for production of disease specific novel therapies acts as a restraint for this market
Segmentation: Global Carcinoid Syndrome Drug Market
By Organ Affected
By Therapy Type
By Route of Administration
By Distribution Channel
Rest of South America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-carcinoid-syndrome-drug-market
Key Developments in the Market:
In February 2018, Ipsen Biopharmaceuticals, Inc received Health Canada approval in Canada for Somatuline Autogel (lanreotide injection) for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs). This new indication of Somatuline Autogel significantly changes the treatment landscape for patients
In February 2017, LEXICON PHARMACEUTICALS, INC received the FDA approval for Xermelo (telotristat ethyl), an oral serotonin inhibitor for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in cancer patients with metastatic neuroendocrine tumor. This approval of Xermelo helps patients suffering from carcinoid syndrome diarrhea throughout the United States
Key Market Players:
Few of the major competitors currently working in the global carcinoid syndrome drug market are Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., LEXICON PHARMACEUTICALS, INC, Ipsen Biopharmaceuticals, Inc, Sirtex SIR-Spheres Pty Ltd, BTG International Ltd, WOCKHARDT, Sun Pharmaceutical Industries Ltd, Amgen Inc, Entrinsic Health Solutions, Inc., Camurus AB, Endo Pharmaceuticals Incand many others
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-carcinoid-syndrome-drug-market
Browse Trending Related Reports @
About Data Bridge Market Research: